Literature DB >> 25233997

Cardiovascular drugs: Engineered apyrase averts clot formation.

Sarah Crunkhorn.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25233997     DOI： 10.1038/nrd4444

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.

Authors:  Douglas Moeckel; Soon Soeg Jeong; Xiaofeng Sun; M Johan Broekman; Annie Nguyen; Joan H F Drosopoulos; Aaron J Marcus; Simon C Robson; Ridong Chen; Dana Abendschein
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956
  1 in total
  2 in total

1.  Apyrase decreases phage induction and Shiga toxin release from E. coli O157:H7 and has a protective effect during infection.

Authors:  Ida Arvidsson; Ashmita Tontanahal; Karl Johansson; Ann-Charlotte Kristoffersson; Sára Kellnerová; Michael Berger; Ulrich Dobrindt; Diana Karpman
Journal:  Gut Microbes       Date:  2022 Jan-Dec

2.  Pharmacological postconditioning with atorvastatin calcium attenuates myocardial ischemia/reperfusion injury in diabetic rats by phosphorylating GSK3β.

Authors:  Linyan Chen; Ping Cai; Zhendong Cheng; Zaibao Zhang; Jun Fang
Journal:  Exp Ther Med       Date:  2017-05-17       Impact factor: 2.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.